TYRA advances oral dabogratinib 60 mg to Phase III in NMIBC
SURF302 interim results for intermediate-risk NMIBC show oral dabogratinib 60 mg with 79% ORR and 64% CR, described as well-tolerated for chronic dosing. The 60 mg dose is advancing to Phase III.
Initial results from the SURF302 study indicate oral dabogratinib at 60 mg showed strong efficacy and safety in intermediate-risk NMIBC, with 79% ORR and 64% CR, and was well tolerated for chronic dosing. The 60 mg dose is advancing to phase III, with the aim of transforming standard care by reducing procedura…